medigraphic.com
Órgano Oficial del Instituto Nacional de Pediatría

2015, Number 1

<< Back Next >>

Acta Pediatr Mex 2015; 36 (1)

Brain nuclear magnetic resonance in patients with late diagnosis of phenylketonuria

Jiménez-Pérez MO, Gómez-Garza G, Ruiz-García M, Fernández-Lainez C, Ibarra-González I, Vela-Amieva M

Language: Spanish
References: 30
Page: 9-17
PDF size: 722.98 Kb.


ABSTRACT

Introduction: Classic phenylketonuria (PKU) is a genetic encephalopathy characterized by impairment of phenylalanine (Phe) metabolism, leading to elevation of blood Phe to toxic levels. Clinical manifestations include irritability, sleep disorders, apathy, seizures, developmental delay, autistic behavior, aggressiveness; mental retardation is the most severe manifestation of the disease.
Objective: To describe the findings of brain nuclear magnetic resonance (NMR) and to measure the apparent diffusion coefficient (ADC) of Mexican PKU patients diagnosed by their clinical manifestations in the National Institute of Pediatrics (INP).
Material and methods: Retrospective analysis of brain images obtained by NMR from PKU patients. A Signa Excite magnet of 1.5 Tesla with an 8-channel phased array cerebral antenna was used. ADC was measured on the Advantage Workstation 4.2p.
Results: Abnormalities in the white and gray matter were observed in all patients; bilateral changes were present in the frontal, temporal, occipital, subcortical and periventricular white matter. ADC was diminished in the peritrigonal and occipital white matter; as well as in the corpus callosum, basal ganglia and cerebellum. One patient had two arachnoid cysts.
Conclusion: All PKU patients exhibited the characteristic NMR abnormalities. The mechanisms responsible for brain damage that occur in PKU patients are poorly understood and require further research.


REFERENCES

  1. Blau N, van Spronsen FJ, Levy HL. Phenylketonuria. Lancet 2010;376:1417-27.

  2. Scriver CR, Kaufman S. Hyperphenylalaninemia: Phenylalanine hydroxylase deficiency. In: Scriver CR, Beaudet AL, Valle D, eds. The metabolic and molecular basis of inherited disease. 8th edn. New York,NY: McGraw-Hill Inc, 2001:1667–724.

  3. Huttenlocher PR. The neuropathology of phenylketonuria: human and animal studies. Eur J Pediatr 2000;159(Suppl 2):S102-6.

  4. Pérez-Dueñas B, Pujol J, Soriano-Mas C, Ortiz H, Artuch R, Vilaseca MA, et al. Global and regional volumen changes in the brains of patients with phenylketonuria. Neurology 2006;66:1074-1078.

  5. Pfaendner NH, Reuner G, Pietz J, Jost G, Rating D, Magnotta VA, et al. MR imaging-based volumetry in patients with early-treated phenylketonuria. Am J Neuroradiol 2005;26:1681-5.

  6. Anderson PJ, Leuzzi V. White matter pathology in phenylketonuria. Mol Genet Metab 2010;99(Suppl 1):S3-9.

  7. Følling A. ÜberAusscheidung von Phenylbrenztraubensäure in den Harnals Stoffwechselanomalie in VerbindungmitImbezillität. Hoppe-Seyler’s Z Physiol Chem 1934;227:169-76.

  8. Aragón MC, Giménez C, Valdivieso F. Inhibition by Lphenylalanine of tyrosine transport by synaptosomal plasmamembrane vesicles: implications in the pathogenesis of phenylketonuria. J Neurochem 1982;39:1185-7.

  9. Herrero E, Aragón MC, Giménez C, Valdivieso F. Tryptophan transport into plasma membrane vesicles derived from rat brain synaptosomes. J Neurochem 1983;40:332-7.

  10. van Spronsen FJ, Hoeksma M, Reijngoud DJ. Brain dysfunction in phenylketonuria: is phenylalanine toxicity the only possible cause? J Inherit Metab Dis 2009;32:46-51.

  11. Bauman ML, Kemper TL. Morphologic and histoanatomic observations of the brain in untreated humanphenylketonuria. Acta Neuropathol 1982;58:55-63.

  12. Cordero ME, Trejo M, Colombo M, Aranda V. Histological maturation of the neocortex in phenylketonuricrats. Early Hum Dev 1983;8:157-73.

  13. Gazit V, Ben-Abraham R, Rudin M, Katz Y. Glucose-lowering effect of beta-phenylpyruvate in neonatal mice: a possible mechanism for phenylketonuria-related neurodegenerative changes. Brain Res Dev Brain Res 2003;141:137-40.

  14. Hörster F, Schwab MA, Sauer SW, Pietz J, Hoffmann GF, Okun JG, et al. Phenylalanine reduces synaptic density in mixed cortical cultures from mice. Pediatr Res 2006;59:544- 8.

  15. Burri R, Steffen C, Stieger S, Brodbeck U, Colombo JP, Herschkowitz N. Reduced myelinogenesis and recovery in hyperphenylalaninemic rats. Correlation between brain phenylalanine levels, characteristic brain enzymes for myelination, and brain development. Mol Chem Neuropathol 1990;13:57-69.

  16. Wyse AT, Sarkis JJ, Cunha-Filho JS, Teixeira MV, Schetinger MR, Wajner M et al. Effect of phenylalanine and its metabolites on ATP diphosphohydrolase activity in synaptosomes from rat cerebral cortex. Neurochem Res 1994;19:1175-80.

  17. Martínez-Cruz F, Pozo D, Osuna C, Espinar A, Marchante C, Guerrero JM. Oxidative stress induced by phenylketonuria in the rat: Prevention by melatonin, vitamin E, and vitamin C.J Neurosci Res 2002;69:550-8.

  18. Sitta A, Barschak AG, Deon M, Terroso T, Pires R, Giugliani R, et al. Investigation of oxidative stress parameters in treated phenylketonuric patients. Metab Brain Dis 2006;21:287-96.

  19. Sitta A, Manfredini V, Biasi L, Treméa R, Schwartz IV, Wajner M, et al. Evidence that DNA damage is associated to phenylalanine blood levels in leukocytes from phenylketonuric patients. Mutat Res 2009;679:13-6.

  20. Ribas GS, Sitta A, Wajner M, Vargas CR. Oxidative stress in phenylketonuria: what is the evidence? Cell Mol Neurobiol 2011;31:653-62.

  21. Simon KR, Dos Santos RM, Scaini G, Leffa DD, Damiani AP, Furlanetto CB, et al. DNA damage induced by phenylalanine and its analogue p-chlorophenylalanine in blood and brain of rats subjected to a model of hyperphenylalaninemia. Biochem Cell Biol 2013;91:319-24.

  22. Huang X, Lu Z, Lv Z, Yu T, Yang P, Shen Y, et al. The Fas/Fas ligand death receptor pathway contributes to phenylalanine-inducedapoptosis in cortical neurons. PLoS One. 2013;8(8):e71553. doi: 10.1371/journal.pone.0071553.

  23. Medici C, Varacchi C, González G. Unusual case of phenylketonuria with atypical brain magnetic resonance imaging findings. J Child Neurol 2012;28:1496-1499.

  24. Cleary MA, Walter JH, Wraith JE, Jenkins JP, Alani SM, Tyler K, et al. Magnetic resonance imaging of the brain in phenylketonuria. Lancet 1994;344:87-90.

  25. Kono K, Okano Y, Nakayama K, Hase Y, Minamikawa S, Ozawa N, et al. Diffusion-weighted MR imaging in patients with phenylketonuria: relationship between serum phenylalanine levels and ADC values in cerebral white matter. Radiology 2005;236:630-636.

  26. Manara R, Burlina AP, Citton V, Ermani M, Vespignani F, Carollo C, et al. Brain MRI diffusion-weighted imaging in patients with classical phenylketonuria. Neuroradiology 2009;51:803-12.

  27. Bodner KE, Aldridge K, Moffitt AJ, Peck D, White DA, Christ SE. A volumetric study of basal ganglia structures in individuals with early-treated phenylketonuria. Mol Genet Metab 2012;107:302-7.

  28. Phillips MD, McGraw P, Lowe MJ, Mathews VP, Hainline BE. Diffusion-weighted imaging of white matter abnormalities in patients with phenylketonuria. Am J Neuroradiol 2001;22:1583-6.

  29. Bahn MM, Kido DK, Lin W, Pearlman AL. Brain magnetic resonance diffusion abnormalities in Creutzfeldt-Jakob disease. Arch Neurol 1997;54:1411-5.

  30. Pradilla G, Jallo G. Arachnoid cysts: case series and review of the literature. Neurosurg Focus 2007;22(2):E7.




2020     |     www.medigraphic.com